Please login to the form below

Not currently logged in


This page shows the latest Remdesivir news and features for those working in and with pharma, biotech and healthcare.

Pearls of wisdom

Pearls of wisdom

The only therapeutics that we have seen with some level of efficacy are remdesivir and dexamethasone.

Latest news

More from news
Approximately 7 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Working together against COVID-19 Working together against COVID-19

    Gilead shared some positive updates on social media about remdesivir but did not address all HCP concerns. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... Yet, it is unlikely that any of the drugs will be a panacea, with Jefferies analysts saying remdesivir “might be modestly helpful”.

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    An experimental antiviral: Gilead’s remdesivir. Gilead’s remdesivir, an experimental antiviral drug, is arguably the most-talked about potential treatment for COVID-19. ... Lane is currently overseeing ongoing studies at the US National Institutes of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....